Cite

    Ferreri, A. et al. (2020). Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation. Hematological oncology. 38 (3), pp. 257-265. [Online].